Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Chk1 inhibitor

DRUG CLASS:

Chk1 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	ACR-368 Sensitive: B - Late Trials ACR-368 Sensitive : B	ACR-368 Sensitive: B - Late Trials ACR-368 Sensitive : B
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	ACR-368 Sensitive: B - Late Trials ACR-368 Sensitive : B	ACR-368 Sensitive: B - Late Trials ACR-368 Sensitive : B
BRCA2 mutation	Ovarian Serous Adenocarcinoma	BRCA2 mutation	Ovarian Serous Adenocarcinoma	ACR-368 Sensitive: C2 – Inclusion Criteria ACR-368 Sensitive : C2	ACR-368 Sensitive: C2 – Inclusion Criteria ACR-368 Sensitive : C2
BRCA1 mutation	Ovarian Serous Adenocarcinoma	BRCA1 mutation	Ovarian Serous Adenocarcinoma	ACR-368 Sensitive: C2 – Inclusion Criteria ACR-368 Sensitive : C2	ACR-368 Sensitive: C2 – Inclusion Criteria ACR-368 Sensitive : C2
BRCA1 mutation	Ovarian Serous Adenocarcinoma	BRCA1 mutation	Ovarian Serous Adenocarcinoma	olaparib + ACR-368 Sensitive: C3 – Early Trials olaparib + ACR-368 Sensitive : C3	olaparib + ACR-368 Sensitive: C3 – Early Trials olaparib + ACR-368 Sensitive : C3
CCNE1 amplification	Ovarian Cancer	CCNE1 amplification	Ovarian Cancer	ACR-368 + LY3300054 Sensitive: C3 – Early Trials ACR-368 + LY3300054 Sensitive : C3	ACR-368 + LY3300054 Sensitive: C3 – Early Trials ACR-368 + LY3300054 Sensitive : C3
PIK3CA mutation	Solid Tumor	PIK3CA mutation	Solid Tumor	ACR-368 + LY3023414 Sensitive: C3 – Early Trials ACR-368 + LY3023414 Sensitive : C3	ACR-368 + LY3023414 Sensitive: C3 – Early Trials ACR-368 + LY3023414 Sensitive : C3
SRSF2 mutation	Acute Myelogenous Leukemia	SRSF2 mutation	Acute Myelogenous Leukemia	ACR-368 Sensitive: C3 – Early Trials ACR-368 Sensitive : C3	ACR-368 Sensitive: C3 – Early Trials ACR-368 Sensitive : C3
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	olaparib + ACR-368 Sensitive: C3 – Early Trials olaparib + ACR-368 Sensitive : C3	olaparib + ACR-368 Sensitive: C3 – Early Trials olaparib + ACR-368 Sensitive : C3
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	olaparib + ACR-368 Sensitive: C3 – Early Trials olaparib + ACR-368 Sensitive : C3	olaparib + ACR-368 Sensitive: C3 – Early Trials olaparib + ACR-368 Sensitive : C3
BRCA wild-type	Triple Negative Breast Cancer	BRCA wild-type	Triple Negative Breast Cancer	ACR-368 Sensitive: C3 – Early Trials ACR-368 Sensitive : C3	ACR-368 Sensitive: C3 – Early Trials ACR-368 Sensitive : C3
BRCA1 3363delGAAA	Triple Negative Breast Cancer	BRCA1 3363delGAAA	Triple Negative Breast Cancer	ACR-368 Sensitive: D – Preclinical ACR-368 Sensitive : D	ACR-368 Sensitive: D – Preclinical ACR-368 Sensitive : D